- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lee Schwartzberg on How Biosimilars Will Help Address Financial Toxicity
We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, or the payer, said Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Transcript
OneOncology announced that its practices have begun administering the 2 cancer biosimilars on the US market. How will this help address financial toxicity?
We were very proud that OneOncology jumped in as the first group to endorse therapeutic biosimilars in the oncology space. We really believe that biosimilars line up as a value accretion for every constituency, whether it’s the patient, the practice, the payer, because you’re giving a high-value drug at a lower cost and therefore across the chain of value, it’s good for everyone. So, there’s education around biosimilars. We’ve been using supportive care biosimilars for a few years.
Some people feel there might be a different bar for therapeutics. I’ve looked at the totality of evidence about what allows a biosimilar to come to market, which is based on a very strong analytic similarity, as well as some clinical trials. We can extrapolate the use of these drugs into the same conditions that we would with the originator drug. I feel very strongly that we’re going to move wholesale into suing biosimilars where there appropriate in the therapeutic oncology space, and it will be great for everyone.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
